Atalanta Therapeutics
Before joining Atalanta, Matt spent over three years at Vertex Pharmaceuticals in analytical development. There he worked on small molecule treatments for multiple rare diseases including cystic fibrosis and alpha-1 antitrypsin deficiency. Matt’s expertise includes HPLC method development and validation. Matt has a B.S. in Chemical Engineering from Lehigh University and a M.S. in Chemistry from Northeastern University.